Otsuka and Oxford HIN Collaborate on Digital Therapeutic for Major Depressive Disorder

Introduction

In an exciting development for mental health treatment, Otsuka Pharmaceutical Europe Ltd. and Otsuka Pharmaceuticals (U.K.) Ltd. have announced a collaboration with Health Innovation Oxford & Thames Valley (Oxford HIN) to evaluate a new digital therapeutic (DTx), CARE for MDD, aimed at treating major depressive disorder (MDD). This partnership aims to leverage Oxford HIN’s extensive network and expertise in mental health treatment along with Otsuka’s experience in developing mental illness therapies to create innovative solutions that extend beyond traditional medication.

Innovative Collaboration for Mental Health

This collaboration marks a significant step forward in supporting patients with MDD. By integrating Oxford HIN’s mental health expertise with Otsuka’s therapeutic development experience, the initiative seeks to develop and implement digital solutions that enhance patient care. Andy Hodge, CEO of Otsuka Europe, highlighted the importance of this collaboration, stating, "Otsuka is committed to supporting patients living with depressive disorder and we are delighted to collaborate with Health Innovation Oxford & Thames Valley."

The Digital Therapeutic: CARE for MDD

CARE for MDD is a regulated medical device delivered through a smartphone app, co-developed by Otsuka and Click Therapeutics Inc. This innovative DTx comprises three key components:

1. Emotional Faces Memory Task (EFMT): A novel cognitive emotional training method.
2. Cognitive Behavioural Therapy (CBT) Lessons: Structured therapy sessions delivered digitally.
3. Personalised SMS Notifications: Customized messages to support patient engagement and adherence.

These components work together to provide a comprehensive digital therapeutic aimed at improving mental health outcomes for patients with MDD.

Pilot Evaluation and Real-World Implementation

The real-world implementation of CARE for MDD will be evaluated through a pilot program across four primary care sites in England: Chineham Medical Practice, Camrose, Gillies & Hackwood (CGH) Partnership, Haxby Group, and St Bartholomew & Hollow Way Medical Practice. Additional sites focusing on primary care and talking therapies are also being considered. This pilot will gather valuable feedback from both patients and healthcare practitioners to inform the wider rollout and potential NHS adoption.

James Rose, Director of Strategic and Industry Partnerships at Oxford HIN, emphasized the significance of this project: "Depression is a significant challenge for the NHS in England, representing a substantial portion of the overall disease burden and affecting millions."

The Potential of Digital Therapeutics and Connected Health Products

Digital therapeutics (DTx) like CARE for MDD represent a new frontier in mental health care. These health software systems are designed to treat or alleviate diseases and disorders through medical interventions delivered digitally. DTx offers several benefits, including increased accessibility, patient privacy, and the empowerment of individuals to manage their symptoms more effectively.

Connected health products, which include digital therapeutics, leverage advanced data-driven tools such as artificial intelligence and machine learning to provide personalized care. These technologies enable continuous monitoring and tailored interventions, significantly enhancing the standard of care. Tim Cooper, GP and Primary Care Champion, highlighted the potential impact, stating, "With primary care facing increasing demand, it’s exciting to be part of the team exploring the potential of digital therapeutics to offer an additional support option for patients and clinicians."

DTx and connected health products are well-positioned to address the challenges in accessing mental health care. They provide healthcare professionals with additional therapeutic options while offering patients privacy and empowerment. These innovations have the potential to improve the quality of life for many individuals, making mental health care more effective and personalized.

Future Implications and NHS Integration

The insights gathered from this collaboration will not only inform plans for expanding access to CARE for MDD across Great Britain but also help facilitate its adoption within the NHS. The success of this pilot could pave the way for broader integration of digital therapeutics into standard mental health care practices, potentially transforming the treatment landscape for MDD.

About Otsuka and Oxford HIN

Otsuka Pharmaceutical is a global healthcare company known for its innovative approach to meeting unmet medical needs, particularly in the field of mental health. The company employs over 34,000 people worldwide and had consolidated sales of approximately €13.27 billion in 2023.

Health Innovation Oxford & Thames Valley, formerly the Oxford Academic Health Science Network, collaborates with the NHS, research, and industry to develop and spread health and social care innovations. Their mission is to improve health outcomes and economic prosperity through pioneering new treatments and approaches.

Conclusion

The collaboration between Otsuka and Oxford HIN represents a promising advancement in the treatment of major depressive disorder. By leveraging cutting-edge digital therapeutic technology and connected health products, this partnership aims to provide more effective, accessible, and personalized care for patients with MDD. As digital therapeutics continue to evolve, their integration into mainstream healthcare practices could significantly enhance the quality of life for those living with mental health conditions.

Further Reading 

For more insights on how AI is maximising ROI in Drug Discovery and Development, download Pharma IQ's Report. 

Find out how AI is Maximising Patient Recruitment and Retention in Clinical Trials with these Frequently Asked Questions.

Join Us to Learn More

Eager to dive deeper and learn how to overcome integration challenges from real-world case studies?

Join industry leaders and experts at the AI Pharma & Healthcare Event, where you can gain firsthand insights into successful AI integration strategies. This is your opportunity to learn from the successes and challenges faced by others and to network with professionals who are at the forefront of AI technology in the pharmaceutical industry.

📅 Event Details:

Event: AI Pharma & Healthcare Summit
Dates: 24-26 September 2024
Location: Amsterdam Marriott Hotel
Event Website: AI Pharma & Healthcare Summit